On the stock market since 2014, it operates in the world of health and science. It has 18 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
The cash pile is strong; debt and other items pull the grade toward the middle.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly below the class average.
Business Quality: Profit power and business quality trail similar companies in the sector.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 59% a year on average.
Sales run at $20.6M a year. A small number, but proof the product has real buyers.
There is $21.3M in the vault; even if every debt were paid off, $19.1M would remain.
A loss of $8.6M against $20.6M in annual sales.
At the current pace of spending, the cash lasts about 2.5 years. After that, the company needs to find new money.
On our five-subject report card, SCYX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: SCYX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.